Who are diltiazem and acetylcystein's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/diltiazem-and-acetylcystein.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

diltiazem and acetylcystein — Competitive Intelligence Brief

diltiazem and acetylcystein (diltiazem and acetylcystein) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker + antioxidant combination. Area: Cardiovascular.

phase 3 Calcium channel blocker + antioxidant combination L-type calcium channel (diltiazem); glutathione synthesis pathway (acetylcysteine) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

diltiazem and acetylcystein (diltiazem and acetylcystein) — University Hospital, Strasbourg, France. This combination uses diltiazem to reduce calcium influx and improve cardiac function while acetylcysteine provides antioxidant and mucolytic support to protect against drug-induced injury.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
diltiazem and acetylcystein TARGET	diltiazem and acetylcystein	University Hospital, Strasbourg, France	phase 3	Calcium channel blocker + antioxidant combination	L-type calcium channel (diltiazem); glutathione synthesis pathway (acetylcysteine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker + antioxidant combination class)

University Hospital, Strasbourg, France · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). diltiazem and acetylcystein — Competitive Intelligence Brief. https://druglandscape.com/ci/diltiazem-and-acetylcystein. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab